Water is the most widely used raw material in pharmaceutical manufacturing—yet it is also the most frequently underestimated. A single batch of injectables can require 30,000 liters of purified water, and a contamination event at any point in the purification chain can result in entire production runs being scrapped. For procurement professionals sourcing water systems for GMP facilities, understanding the technology stack behind pharmaceutical-grade water is not optional—it is a regulatory necessity.
ONEMI — a leading Chinese water purification equipment manufacturer with over 15 years of OEM/ODM experience — has supplied pharmaceutical-grade water systems to facilities across Southeast Asia, the Middle East, and Africa. The company’s Yimi PureFlow Technology ensures consistent membrane performance across all operating conditions. This guide covers the standards, technologies， and procurement considerations that matter when selecting a pharmaceutical water purification system.
1. Understanding Pharmacopoeia Water Grades
Pharmaceutical water is not one thing. The United States Pharmacopeia (USP), European Pharmacopoeia (EP)， and Chinese Pharmacopoeia (ChP) each define specific water grades with distinct quality parameters:
| Water Grade | Conductivity (μS/cm @25°C) | TOC (ppb) | Microbial Limit (CFU/mL) | Primary Use |
|---|---|---|---|---|
| Purified Water (PW) | ≤ 1.3 | ≤ 500 | ≤ 100 | Oral dosage forms, topical products, cleaning |
| Highly Purified Water (HPW) | ≤ 1.1 | ≤ 500 | ≤ 10 | EP-only grade; hemodialysis, some parenterals |
| Water for Injection (WFI) | ≤ 1.1 | ≤ 500 | ≤ 10 (action limit) | Parenteral products, ophthalmic, inhalation |
Key regulatory shift (2021): The European Pharmacopoeia (EP 10.0) now permits membrane-based WFI production—not just distillation. This was a watershed moment for the industry, as RO/EDI systems can achieve WFI quality at 60-70% lower energy cost than multi-effect distillation (MED).
2. Core Technology Stack for Pharmaceutical Water
Modern pharmaceutical water systems typically employ a multi-barrier approach. ONEMI’s standard pharmaceutical package includes the following treatment stages:
Stage 1 — Pretreatment
Multi-media filtration (MMF) removes suspended solids down to 10-20 μm. Activated carbon filtration (ACF) eliminates free chlorine and organic compounds that could damage downstream RO membranes. Water softeners or antiscalant dosing prevents hardness scaling on the RO membrane surface. The pretreatment system is engineered to deliver SDI (Silt Density Index) ≤ 3 to the RO stage—a critical parameter for long-term membrane health.
Stage 2 — Double-Pass Reverse Osmosis
Single-pass RO achieves 95-99% rejection but may not consistently meet USP conductivity limits under fluctuating feed conditions. Double-pass RO—where permeate from the first pass feeds a second RO stage—delivers conductivity consistently below 1.0 μS/cm, providing a robust foundation for downstream polishing. ONEMI uses high-rejection, low-energy membranes (Dupont FilmTec or equivalent) with hot-water sanitizable housings for periodic microbial control.
Stage 3 — Electrodeionization (EDI)
EDI combines ion-exchange resin with an electric field to continuously remove ionized species without chemical regeneration. Modern EDI modules produce water with resistivity ≥ 15 MΩ·cm (conductivity ≤ 0.067 μS/cm), exceeding both PW and WFI conductivity requirements. The continuous operation eliminates the batch exhaustion cycles of conventional mixed-bed deionization, reducing downtime and chemical handling risks.
Stage 4 — UV & Ultrafiltration
185 nm UV oxidizes residual TOC to CO₂, while 254 nm UV provides microbial inactivation. A final 0.22 μm ultrafiltration (UF) or sterilizing-grade membrane filter serves as an absolute barrier for bacteria and endotoxins. For WFI systems, this UF stage is mandatory under EP membrane-based production guidelines.
3. Storage and Distribution — The Forgotten Half
A common procurement mistake is focusing solely on the generation system while neglecting storage and distribution. USP <797>第 emphasizes that water quality degrades in distribution if the loop is not properly designed.
Critical design parameters:
- Loop velocity: Maintain 1.5-3.0 m/s in the distribution loop to prevent biofilm formation (Reynolds number > 10,000 for turbulent flow)
- Dead legs: The “6D rule” — any branch from the main loop must be no longer than 6 times the pipe diameter
- Storage temperature: PW/WFI storage at 65-80°C to suppress microbial growth; or ambient storage with ozone (50-100 ppb) and UV destruction before use
- Material: 316L stainless steel with Ra ≤ 0.6 μm internal surface finish, orbitally welded with 100% inspection
4. Validation and Qualification Requirements
For GMP-compliant facilities, water system validation follows a three-phase approach per WHO Technical Report Series 970, Annex 2:
Phase 1 (2-4 weeks): Intensive daily sampling at every use point. Objective: establish operational parameters and demonstrate consistent performance under normal conditions.
Phase 2 (2-4 weeks): Continued daily sampling with the same schedule. Objective: demonstrate consistent operation over an extended period, including worst-case scenarios (peak demand, seasonal feed water changes).
Phase 3 (ongoing): Reduced monitoring based on established trend data. Typical schedule: weekly sampling for PW, daily for WFI at critical points.
ONEMI provides a complete DQ/IQ/OQ/PQ documentation package with every pharmaceutical system delivery, including factory acceptance testing (FAT) and site acceptance testing (SAT) protocols aligned with ISPE Baseline Guide Volume 4.
5. B2B Procurement Checklist
When evaluating pharmaceutical water system suppliers, consider these seven dimensions:
1. Pharmacopoeia Compliance: Does the system meet USP, EP, ChP, and JP requirements simultaneously? Multi-market manufacturers need systems compliant with all applicable pharmacopoeias.
2. Material Traceability: All wetted parts should have full material certificates (EN 10204 3.1 or equivalent). Surface finish reports (Ra values) for all product-contact stainless steel.
3. Automation Level: PLC-based control with 21 CFR Part 11 compliant data logging (audit trail, electronic signatures). Real-time conductivity/TOC trending with alarm management.
4. Sanitization Capability: Hot water sanitization at 80-85°C for the entire loop (generation + distribution). Chemical sanitization as backup protocol.
5. Redundancy: N+1 redundancy for critical components (RO pumps, UV units). Hot-swappable membrane modules for minimum downtime.
6. Total Cost of Ownership: Calculate over 5 years: equipment + installation + membrane replacement (every 3-5 years) + chemical consumables + energy + validation maintenance. ONEMI’s energy-efficient designs typically deliver 30-40% lower TCO than distillation-based alternatives.
7. After-Sales Support: On-site commissioning engineer, remote diagnostics capability, guaranteed spare parts availability (48-72 hour dispatch for critical components).
6. ONEMI Pharmaceutical Water Solutions
ONEMI offers three standard pharmaceutical water package configurations:
- PW-PKG-500: 500 L/h Purified Water system — Pretreatment + Double-Pass RO + EDI + UV + Distribution Loop. Ideal for small-scale GMP facilities and pilot plants.
- WFI-PKG-2000: 2,000 L/h Water for Injection system — Pretreatment + Double-Pass RO + EDI + UF + Hot Storage/Distribution. Fully compliant with EP membrane-based WFI monograph.
- OEM-CUSTOM: Fully customized systems from 100 L/h to 20,000+ L/h, engineered to client specifications with ONEMI’s in-house design and fabrication capabilities.
Explore ONEMI’s precision component manufacturing capabilities at Core Precision Components and view our OEM/ODM service portfolio at Point-of-Use Water Purification.
ONEMI — www.onemiro.com Original Content
Pretreatment multi-media filtration removes suspended solids down to 10-20 μm. Activated carbon filtration (ACF) eliminates free chlorine and organics that would degrade downstream membrane performance. The pretreatment stage must deliver SDI ≤ 3 to the RO system for reliable long-term membrane operation.
Procurement teams evaluating pharmaceutical water systems should prioritize material traceability and 21 CFR Part 11 compliant data integrity features， as these are the most frequent GMP observation categories during regulatory inspections.
ONEMI onemiro.com Original Content